Alzheimer’s Drug Failure Leaves Scientists Seeking New Direction
bloomberg.com
bloomberg.com
https://www.alzheimers.net/research-spending-vs-annual-care-...
Finding a cure or delaying symptoms by a decade would save a lot of money.
Let’s add $10 billion to the federal research budget and add a motivated czar to oversee the research. Wonder if Bill Gates has a few extra cycles.
We know we can’t completely replace exercise with a drug because mechanical stress is part of the process. So, drugs might work on Alzheimer’s patients, but without knowing the cause it’s still up in the air.
We have no idea if it’s caused by a pathogen or something else, or even if it’s a single disease or several related diseases.
Alzheimer's is an underfunded disease given the amount that it costs us in healthcare. I'm saying we should spend a lot more money and put someone in charge of the money who will spend it effectively.
Further spending more money does not give linear increases in value. Bumping up from around 2 bullion a year sounds great from a budget standpoint, but do we have another 8 Billion dollars worth of promising research to do next year and people able to carry that out? We are already ramping up funding rapidly, but there are only so many specialists out there.
I never claimed that if we doubled the money, we'd get double the research. I simply threw out a SMALL number like $10 billion a year. We spend $28 billion on HIV, for example.
https://www.hiv.gov/federal-response/funding/budget
I've read lots of articles over the decades about how AIDS would never be cured. Now you can live a long productive life with the disease.
PS: People talk about the huge improvement in AIDS treatments, but by default people where often living 15+ years after infection. Note infection not detection. Extending that was always considered a viable approach.
No one is trying to violate any laws of physics by researching Alzheimer’s, the brain, etc.
I am not arguing it’s likely, only a very real possibility. Because in the end biology is physics, and therefore must deal with it.
Polio have been eradicated in developed nations by the 1980s.
https://www.forbes.com/sites/denizcam/2017/11/13/microsoft-b...
Edit: Example. In 2010 he gave $3.5 million to charter schools in Newark, NJ. This has contributed to overall increase in success rates in such schools, which has boosted the entire city's graduation rates. They've increased significantly each year since 2013, which is about the first year you'd expect to see the results of such a grant on 4-year programs like HS.
I'm glad we have some billionaires trying alternative, independent paths to success!
The problem is that they found what everybody knows but doesn't want to admit. The current public school system is about optimal for the amount of resource being spent. There is no mythical "pile of waste" that you can magically draw from.
They found that focused resource does help outcomes, but in far less proportion than the increase. If you want 5% improvement in achievement, you need closer to 25% increase in resource--and it needs to be sustained over years. More teachers that are better qualified is a good idea, but that is also the most expensive choice. And, your most effective option is to spend almost all your resource on the lowest achievers. All of these are highly politically unpalatable in the US.
Belated reply, catching up on my reading.
This is a very interesting point.
I live in a largish school district. I've long believed, but cannot prove, that it's just too big. eg Scale matters. Everyone I've ever met who has ties to the district agrees with me.
I know the CFO. He crunched some numbers, comparing cost per student and outcomes. Although he wouldn't share the data with me (political suicide), he related that the it's a bathtub distribution.
So, I believe, but cannot prove, there's an optimal range for most organizations, and education reformers would get a lot of mileage out of correct sizing their districts.
0. https://www.alz.org/media/HomeOffice/Facts%20and%20Figures/f...
The present generation of Alzheimer's patients has a big problem, too. Grants for research into Alzheimer's are controlled by the present generation of researchers, who have no particular desire to learn that Alzheimer's is an infectious disease. So, negligible work is going into establishing an infectious-disease etiology, never mind effective treatment. Publications supporting an infectious-disease cause of Alzheimer's are, likewise, not especially welcomed by established Alzheimer's referees.
The herpes-family observations go back twenty years, and are only now gaining traction. The gingivalis observations are more recent.
This is an area where one wealthy donor could make an enormous difference that might improve the lives of millions in a very short time.
> A new scientific truth does not triumph by convincing its opponents and making them see the light, but rather because its opponents eventually die, and a new generation grows up that is familiar with it.
Science has been able to deal with this problem for a long time.
Mutations in the APP (amyloid precursor protein), PSEN1, and PSEN2 genes are shown to cause early onset AD with very high penetrance.
Here’s an overview of AD genetics: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044597/
One interesting comment from this article: “...which subsequently led to the cloning of the APP type I integral membrane glycoprotein from which Aβ is proteolytically derived. The APP gene was then mapped to chromosome 21q, which accounted for the observation that patients with Down syndrome (trisomy 21) develop amyloid deposits and the neuropathological features of AD when in their 40s”
As an example, a range of anticonvulsant drugs exhibit neuroprotective effects. Depakote appears to be the best studief of the lot for this, but that's not saying much.Something like lamotrogine has similar results with lower side effect profile. These are widely used drugs for diseases like epilepsy, but they are also used for a wide range of mental health diseases where psychosis and dementia are issues because they are very effective in those areas as well. A nice bonus in treating another disease with similar neuro symptoms.
This probably wouldn't be front-line treatment, but alongside amyloid reducing medications could form a powerful combination. The biggest obstacle might be the side effects, but judicial use in the earliest stages or in high risk poulations would probably be useful. The problem is right now the data is limited to very small studies or anecdotal case studies of individual patients that were treated off label.
The patent is for problem + solution. You can patent many solutions for one problem and also a solution for many problems.
If they prove, say, that vitamin C stops Alzheimer's then they can patent it for that usage.
You see this a lot in cancer treatment and it makes a lot of sense. In a proper functioning system (i.e. not the USA±) it's a pretty decent solution.
± Seriously, the system there is designed so all in theory competing components are incentivized to work against consumer interests. Same thing with the housing market pushing house prices (5% interest on 500k is more $ then 5% on 200k, house sellers/older owners think they're rich but only benefit when they sell and downsize; only winners are lenders and real estate investors).
Here is an article discussing this approach:
http://stm.sciencemag.org/content/6/248/248fs30
I call them "use patents" but I am not sure if that is an official term or just a colloquialism.
Here's an example: https://en.wikipedia.org/wiki/Pregabalin
That's an epilepsy treatment which also worked for nerve damage. They weren't allowed to dispense the generic for nerve problems. However in practise the prescriptions don't include the reason so in practise they provided the generic.
That means that even testing the half dozen or so anticonvulsants known to have neuroprotective benefits it would cost in the range of $100 million.
But for the sake of argument, let's grant your premise anyway and see where it leads. Let's say it costs billions, even $20 billion to do the trials. The annual cost of Alzheimers may top $250 billion. So the cost/benefit analysis still works out either way. In fact, in that context the potential savings make the difference between $100 million and $20 billion pretty negligible if the drugs could normalize even a few years for the average patient that would otherwise be plagued with dementia.
[0] https://www.outsourcing-pharma.com/Article/2018/09/26/Clinic...
Social impact bonds are an interesting idea that might help solve this, although I know little about the practicalities. Specifically, a company would pay for the research and trials, and if it's effective, the government (say, the NHS in the UK) would pay a portion of the money saved to the company.
Just to be clear I think it's worth testing but just not especially more than the 500 other drugs that there is credible reason to think they'd work.
Actual trials haven't been done, but anecdotal data from individual case studies show promise. It's absolutely not a silver bullet or potential full cure. It could however be part of a cocktail of drugs that provide significant improvement. Or maybe not. But the incremental cost if studying an already approved drug is negligible compared to creating new drugs from scratch or continuing research on other experimental drugs. But by all means, both kinds of research should occurr.
Over time with age and with brain damage, older adults lose the ability to generate this type of sleep, and so there is less cleaning.
Does anyone know any more about this? It seems plausible that the cause could be partly due to a loss of this sleep cleaning function. Indeed lack of sleep is correlated with alzheimers.
But that's just a book anecdote. I'd be curious to read more.
The neural maintenance that occurs during sleep, the body's circadian mechanisms and quality of diet all seem to be highly complementary and ultimately point towards a more holistic and fundamental understanding of the disease (or brain physiology in general). It's been demonstrated pretty comprehensively that quality of diet and timing of eating have a profound effect on how well the body functions as a whole, so the sleep component seems to be an important thread in tying all of these approaches together.
"We conclude that the term “type 3 diabetes” accurately reflects the fact that AD represents a form of diabetes that selectively involves the brain and has molecular and biochemical features that overlap with both type 1 diabetes mellitus and T2DM."
Provision of ketones alone reversed this energy starvation. The PET scan literally lit up like a Christmas tree — turned from all blue/black to red!
It was near the end of the presentation...
If neural cellular degeneration is the target of any Alzheimer’s management strategy, wouldn’t dramatic energy consumption declines over decades before cell death, and reversal of these declines after a short treatment be of specific interest?
I think there are many causes with many similar symptoms, which is why no-one has discovered a common cause.
Alzheimer’s is a little odd in that most (maybe all) patients seem to have the plaques. Removing the plaques seems to do nothing though so it might be a side effect of something else going wrong.
This line of thought was originally discounted, under the (mistaken) belief that the blood/brain barrier made this impossible.
I can't think of anything more depressing than working your whole life so you can retire only to go into retirement and be diagnosed with Alzheimer's.
I'd advise a sensible diet and enjoying life while you are young. Don't spend time ruminating about what might kill you when you're near the end of your life regardless.
Edit to add: none of us are guaranteed anything. You could get cancer and be dead at 40. Or younger. Avoiding reckless risks is one thing. Thinking you really have much control over diseases you might get in 40 years from now is another.
It would be interesting to see how brain function continues to be impaired even while the beta amyloids are suppressed using these drugs, helping us get to the real process.
According to my understanding of the amyloid cascade hypothesis, the amyloid beta accumulation is not a cause but indeed a symptom (of gene mutations/something). Then, the amyloid beta basically clumps up and other mechanisms happen and neurons get damaged and this collective damage is known as Alzheimer's Disease.
So the amyloid beta is just one link in the chain.
Even with a complete removal of that link (removing/reducing amyloid beta), one cannot expect the disease to be reversed, since removal of something in-between does not revert the already occured damage. But accumulation of new damage might slow down. Coupled with improved early detection even this would be very helpful to many people.
As far as I know, some modest slowing down was observed in some of the clinical trials. This could mean the amyloid cascade hypothesis isn't completely wrong.
Now, what I found really, really interesting is that first Biogen gets ca. 20 % of its market value vaporized after the aducanumab (a joint venture betwen Biogen and Eisai). This is nearly 20 billion USD. Then, Eisai informs that they still go forward with another substance called BAN2401.
The BAN2401 also targets amyloid beta, but in a different way than others (protofibrils).
So... I'm thinking here that this is either a genius move or a really dumb one. It cannot really be anything in-between. I honestly hope it'll be a genius move.
You're missing a few words here. Was it "the aducanumab trial failed"?
It's the maddening thing about biology. It's a brutal intellectual undertaking. You could have spent your life studying amyloid. Imagine sitting in your office with your stacks of papers now, considering what you have done with your life.
Science is about discovery, not outcome.
And I would love if there were independent studies that could confirm Bredesen's writings (I do not say there are none, just that I am not aware of them).